JP2008536851A5 - 女性でテストステロンおよび関連ステロイドの濃度を増加させる医薬組成物および医薬キット - Google Patents

女性でテストステロンおよび関連ステロイドの濃度を増加させる医薬組成物および医薬キット Download PDF

Info

Publication number
JP2008536851A5
JP2008536851A5 JP2008506606A JP2008506606A JP2008536851A5 JP 2008536851 A5 JP2008536851 A5 JP 2008536851A5 JP 2008506606 A JP2008506606 A JP 2008506606A JP 2008506606 A JP2008506606 A JP 2008506606A JP 2008536851 A5 JP2008536851 A5 JP 2008536851A5
Authority
JP
Japan
Prior art keywords
testosterone
aqueous alcohol
alcohol gel
therapeutic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008506606A
Other languages
English (en)
Other versions
JP2008536851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/013550 external-priority patent/WO2006113242A2/en
Publication of JP2008536851A publication Critical patent/JP2008536851A/ja
Publication of JP2008536851A5 publication Critical patent/JP2008536851A5/ja
Pending legal-status Critical Current

Links

Claims (7)

  1. それを必要とする哺乳類の雌におけるテストステロン欠乏障害の治療、予防、またはその発病リスクの軽減のための経皮投与水性アルコールゲル医薬組成物であって、
    a.0.1%から10%(w/w)のテストステロン、またはその塩、エステル、アミド、鏡像異性体、異性体、互変異性体、プロドラッグもしくは誘導体、
    b.約30%〜約98%(w/w)のエタノールまたはイソプロパノールからなる群から選択されるアルコール、
    c.0.1%から5%(w/w)の浸透促進剤、
    d.0.1%から5%(w/w)のゲル化剤、および
    e.バランス純水、
    を含み、前記組成物が、投与後24時間以内にテストステロン血清濃度を少なくとも3pgテストステロン/ml血清に上昇させる速度および期間で皮膚にテストステロンを放出することができる。
  2. 前記組成物が性ホルモン結合グロブリンの合成を抑制する作用物質、プロゲステロン、プロゲスチンまたはエストロゲン様ホルモンを含む治療剤を0.01%から69%さらに含む、請求項1の水性アルコールゲル。
  3. 前記治療剤がプロゲステロンである請求項1または2の水性アルコールゲル。
  4. 前記治療剤がエストロゲンである請求項1または2の水性アルコールゲル。
  5. 前記治療剤がメチルテストステロンである請求項1または2の水性アルコールゲル。
  6. 前記治療剤がエストラジオールである請求項1または2の水性アルコールゲル。
  7. それを必要とする女性対象の性的能力を改善するための医薬キットあって、
    (a)経皮投与のための水性アルコールゲル医薬組成物であって、
    i.0.1%から10%(w/w)のテストステロン、またはその塩、エステル、アミド、鏡像異性体、異性体、互変異性体、プロドラッグもしくは誘導体、
    ii.30%〜98%(w/w)のエタノールまたはイソプロパノールからなる群から選択されるアルコール、
    iii.0.1%〜5%(w/w)の浸透促進剤、
    iv.0.1%〜5%(w/w)のゲル化剤、および
    v.バランス水
    を含む水性アルコールゲル医薬組成物と、
    (b)性的能力を改善するための作用物質と、
    を含む。
JP2008506606A 2005-04-13 2006-04-11 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 Pending JP2008536851A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67075305P 2005-04-13 2005-04-13
PCT/US2006/013550 WO2006113242A2 (en) 2005-04-13 2006-04-11 Method of increasing testosterone and related steroid concentrations in women

Publications (2)

Publication Number Publication Date
JP2008536851A JP2008536851A (ja) 2008-09-11
JP2008536851A5 true JP2008536851A5 (ja) 2009-05-28

Family

ID=37115670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506606A Pending JP2008536851A (ja) 2005-04-13 2006-04-11 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法

Country Status (7)

Country Link
US (1) US20070154533A1 (ja)
EP (1) EP1868590A4 (ja)
JP (1) JP2008536851A (ja)
KR (1) KR20080016552A (ja)
CA (1) CA2604431A1 (ja)
NO (1) NO20075821L (ja)
WO (1) WO2006113242A2 (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
JP2007537247A (ja) 2004-05-11 2007-12-20 エモーショナル ブレイン ビー.ブイ. 女性性的機能不全の治療における薬学的製剤およびその使用方法
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2011496A1 (en) * 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
CA2704117C (en) * 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
CA2822435C (en) 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20110202362A1 (en) * 2010-02-17 2011-08-18 Western Holdings, Llc Weight loss method and system for performing and monitoring the same
AU2011329782A1 (en) 2010-11-18 2013-06-20 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
JP6562630B2 (ja) * 2011-05-13 2019-08-21 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与用の低投薬濃度テストステロンゲル製剤および無オルガズム症または性的欲求低下障害を治療するためのその使用
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
CN105188670B (zh) 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
WO2016033556A1 (en) * 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN109982691A (zh) 2016-10-06 2019-07-05 韩国迪外天然健康株式会社 包含松醇、d-手性肌醇或它们的类似化合物作为有效成分的用于改善、预防或治疗女性更年期症状的组合物
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
WO2023048174A1 (ja) * 2021-09-22 2023-03-30 テイカ製薬株式会社 角膜疾患治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2423899T3 (es) * 2000-08-30 2013-09-25 Unimed Pharmaceuticals, Llc Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
DE60139625D1 (de) * 2001-12-07 2009-10-01 Besins Int Belgique Gel oder Lösung enthaltend Dihydrotestosterone, deren Herstellungsverfahren und Verwendung
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer

Similar Documents

Publication Publication Date Title
JP2008536851A5 (ja) 女性でテストステロンおよび関連ステロイドの濃度を増加させる医薬組成物および医薬キット
JP4293293B2 (ja) エストローゲン、プロゲスチンあるいはそれら混合物の新規なる経皮投与用組成物
CA2451725C (en) Therapeutic combinations for the treatment of hormone deficiencies
Kuhl Pharmacokinetics of oestrogens and progestogens
CA2419573C (en) Method of increasing testosterone and related steroid concentrations in women
US20030022877A1 (en) Method of increasing testosterone and related steroid concentrations in women
US20150250801A1 (en) Androgen pharmaceutical composition and method for treating depression
JP2009512658A5 (ja)
AU2012210691B2 (en) Testosterone formulations
JP2008538753A5 (ja) 骨の老化または骨粗しょう症の治療または予防用組成物
CA2533312A1 (en) Transdermal hormone delivery system: compositions and methods
US20110306582A1 (en) Androgen pharmaceutical composition and method for treating depression
AU2001285367A1 (en) Method of increasing testosterone and related steroid concentrations in women
JP2016505006A5 (ja)
CA2519980A1 (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ES2340925T3 (es) Sistema de suministro transdermico de gestodeno.
CA2380769A1 (en) Transdermal delivery of lasofoxifene
JP4965263B2 (ja) 浸透増強剤を必要としないホルモンの経皮送達
AU2003228314C1 (en) Androgen pharmaceutical composition and method for treating depression
JP2000143513A (ja) 外用組成物
JP2002087964A (ja) 性機能低下を治療するための医薬組成物及び方法
RU2286787C2 (ru) Способ повышения концентрации тестостерона и родственных стероидов у женщин
Prasad International Journal of Nanomedicine and Nanosurgery
Messerlian et al. Urinary phthalate metabolite concentrations were associated with pregnancy loss among women conceiving with medically assisted reproduction
CA2501846A1 (en) Therapeutic combinations for the treatment of hormone deficiencies